Abstract
As a single agent, interferon-alpha (IFN-alpha) can induce remissions, mostly partial, in a large fraction of patients with indolent lymphomas, including the low grade B-cell lymphomas and cutaneous T-cell lymphoma. In aggressive lymphomas, IFN has minimal activity, and in Hodgkin's disease the limited available experience suggests only modest activity. In indolent B-cell lymphomas, IFN has been integrated with chemotherapy in several large trials: the majority of these trials indicate a favorable impact on failure-free survival; a survival benefit of IFN has been reported by the French-Belgian group. Updated results are now available from a previously reported trial from the MD Anderson Cancer Center that also indicate an apparent survival benefit when IFN is used in conjunction with chemotherapy in patients with indolent B-cell lymphoma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
